Clinical Trial: N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07049432) titled 'N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas' on June 25.

Brief Summary: The purpose of this clinical trial is to learn whether the study drug N-803 is safe and tolerable in patients with B-cell non-Hodgkin lymphoma who have undergone CAR T-cell therapy.

Study Start Date: Sept., 2025

Study Type: INTERVENTIONAL

Condition: B-cell Non Hodgkin Lymphoma

Intervention: DRUG: N803

N-803 will be subcutaneously (SubQ) administered on day 1 of each 21-day cycle for up to 6 cycles.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: University of Utah

Published by HT...